scholarly journals Contracting for perennial energy crops and the cost-effectiveness of the Biomass Crop Assistance Program

Energy Policy ◽  
2020 ◽  
pp. 112018
Author(s):  
Tanner McCarty ◽  
Juan Sesmero
Energies ◽  
2021 ◽  
Vol 15 (1) ◽  
pp. 131
Author(s):  
Dariusz Kwaśniewski ◽  
Aleksandra Płonka ◽  
Paweł Mickiewicz

This study aimed to assess biomass production costs from perennial energy crops, such as Miscanthus giganteus, Sida hermaphrodita, and coppiced willow, in selected agricultural holdings. This assessment was based on applied technologies for harvesting the biomass of the energy crops mentioned above. The scope of the study included research on ten farms located in Małopolska and establishing the possibility of biomass production from selected energy crops in these entities. Biomass production costs have been estimated using the computer application “Bioalkylation”. The result of the research was the answer to the question: what can be the cost range of biomass production from perennial energy crops for the crops Miscanthus giganteus, Sida hermaphrodita, and coppiced willow as the most popular plants? The study shows that production costs depend primarily on the harvesting technology used and the machinery used in the farm. The harvest with rotary mowers, small presses, and windrows was applied regarding Miscanthus giganteus and Sida hermaphrodita. The costs of biomass production were, on average, 424.7 EUR ha−1 for Miscanthus giganteus and 278.9 EUR ha−1 for Sida hermaphrodita. Concerning tonne, this was 37.6 EUR t−1 for Miscanthus giganteus and 30.0 EUR t−1 for Sida hermaphrodita, respectively. In the case of harvesting energy willow, in the form of whole shoots, inefficient and labour-intensive technologies using chainsaws and combustion cutters were applied. The biomass production costs were thus the highest among the assessed plants and amounted, on average, to 612.1 EUR ha−1, which in terms of tonne corresponded to a value of 30.6 EUR. The obtained results and the analysis presented in the paper may help in planning the cultivation of perennial energy crops in order to obtain biomass used for heating purposes on a farm.


2017 ◽  
Vol Volume 9 ◽  
pp. 99-106 ◽  
Author(s):  
Qiang Shi ◽  
Shanlian Hu ◽  
Wesley Furnback ◽  
Gregory Guzauskas ◽  
Jiejing Shen ◽  
...  

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4696-4696
Author(s):  
Bin Wu ◽  
Hua Zhong ◽  
Giuseppe Saglio ◽  
Fangyuan Chen

Abstract Abstract 4696 Purpose: To evaluate the economic outcome of conventional and targeted therapies of patients with chronic myelogenous leukemia (CML). Methods: Two Markov simulation models were designed to measure the cost and quality-adjusted life years (QALYs) for newly diagnosed CML patients whether to be administered conventional therapy or six tyrosine kinase inhibitors (TKIs) based strategies. Clinical and utility data were taken mostly from the literature by a MEDLINE search. Costs were based on local charges. The primary output was reported in terms of incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were performed to examine the robustness of the model output. The impact of patient assistance program (PAP) was assessed. Results: The imatinib plus peginterferon-Á switch 2nd TKIs strategy yielded the most health benefits for newly diagnosed CML patients when compared with the conventional, imatinib switch 2nd TKIs, imatinib switch conventional, imatinib plus IFN-Á switch conventional, nilotinib switch conventional and dasatinib switch conventional strategies (figure 1). Marginal cost-effectiveness was $79,134 or $17,600 per QALY gained relative to conventional strategy without or with PAP (figure 2). Both the nilotinib and dasatinib based strategies were more expensive yet less effective than the alternative strategies and were therefore dominated. Model outputs were sensitive to the cost of TKIs. Conclusion: Imatinib and imatinib plus peginterferon-Á based strategies are potentially more cost-effective and 2nd-generation TKIs may be preferred in the setting of imatinib failure. Patient assistant program in health resource limited setting might notably improve the economic outcome of TKIs based therapies. Disclosures: No relevant conflicts of interest to declare.


2015 ◽  
Author(s):  
Hasan Basirir ◽  
Alan Brennan ◽  
Richard Jacques ◽  
Daniel Pollard ◽  
Katherine Stevens ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document